Rituximab BS (rituximab biosimilar) / Kyowa Kirin, Sandoz - LARVOL DELTA

Kyowa Kirin Announces Approval for Partial Change of Rituximab Biosimilar Received by Sandoz in Japan (Fujifilm Kyowa Kirin Biologics Press Release) - "Kyowa Kirin Co., Ltd...announced that Sandoz KK....its strategic partner of the anti-CD20 monoclonal antibody Rituximab biosimilar which Kyowa Kirin markets in Japan, has received approval for the partial change of Rituximab biosimilar for the treatment of refractory nephrotic syndrome (frequently relapsing or steroid-dependent)."

Japan approval • Renal Disease

Result presentation fiscal 2018 first quarter (Kyowa Hakko Kirin Pharma Press Release) - Launched in Japan in Jan 2018.

Launch Japan • Biosimilar